Research advances in autoantibodies of autoimmune diabetes
Received:July 01, 2015  Revised:July 29, 2015
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2016.01.017
Key words:autoimmune diabetes  islet related autoantibodies  diagnosis  prediction  combined testing
Author NameAffiliationE-mail
LIU Yi-Wen, LI Yu-Xiu* Department of Endocrinology, Key Laboratory of Endocrinology of ex-Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China liyuxiu@medmail.com.cn 
Hits: 2037
Download times: 2483
Abstract:
      Autoimmue diabetes is characterized by the damages in pancreatic β cells mediated by T cells and the presence of islet autoantibodies in the circulation. The initiation of autoimmune is the key step in its pathogenesis. Autoantibodies are the most reliable biomarkers for type 1 diabetes mellitus (T1DM), and widely used in clinical practice, especially in the prediction and diagnosis of T1DM. Though islet related autoantibodies are diverse with various features, glutamic acid decarboxylase antibodies (GADA), insulin autoantibodies (IAA), insulinoma-associated protein 2 antibodies (IA-2A) and zinc transporter-8 antibodies (ZnT8A) are the main islet related autoantibodies applied clinically. In addition, combined testing of islet related autoantibodies is of important significance in the prediction and diagnosis of T1DM.
Close